Insider Selling: Myovant Sciences Ltd. (NYSE:MYOV) Insider Sells 2,008 Shares of Stock

Myovant Sciences Ltd. (NYSE:MYOV – Get Rating) insider Lauren Merendino sold 2,008 shares of the firm’s stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $26.89, for a total value of $53,995.12. Following the sale, the insider now directly owns 169,538 shares in the company, valued at approximately $4,558,876.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Myovant Sciences Stock Up 0.1 %

Shares of NYSE:MYOV opened at $26.89 on Monday. Myovant Sciences Ltd. has a 52-week low of $7.67 and a 52-week high of $27.02. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -13.45 and a beta of 2.20. The business has a 50-day moving average price of $26.87 and a 200-day moving average price of $21.93.

Myovant Sciences (NYSE:MYOV – Get Rating) last announced its quarterly earnings data on Wednesday, October 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $104.82 million during the quarter, compared to analysts’ expectations of $92.00 million. As a group, equities analysts anticipate that Myovant Sciences Ltd. will post -1.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MYOV shares. StockNews.com started coverage on Myovant Sciences in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. SVB Leerink cut Myovant Sciences from an “outperform” rating to a “market perform” rating and increased their price target for the company from $23.00 to $27.00 in a research note on Monday, October 24th. Finally, Robert W. Baird cut Myovant Sciences from an “outperform” rating to a “neutral” rating and increased their price target for the company from $20.00 to $27.00 in a research note on Monday, October 24th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MYOV. SeaCrest Wealth Management LLC purchased a new position in shares of Myovant Sciences in the second quarter worth about $25,000. Lazard Asset Management LLC purchased a new position in Myovant Sciences during the second quarter valued at approximately $70,000. Quantbot Technologies LP purchased a new position in Myovant Sciences during the second quarter valued at approximately $96,000. Y Intercept Hong Kong Ltd purchased a new position in Myovant Sciences during the second quarter valued at approximately $139,000. Finally, Arizona State Retirement System raised its position in Myovant Sciences by 13.5% during the second quarter. Arizona State Retirement System now owns 11,452 shares of the company’s stock valued at $142,000 after acquiring an additional 1,363 shares in the last quarter. 30.62% of the stock is currently owned by hedge funds and other institutional investors.

About Myovant Sciences

(Get Rating)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.